Literature DB >> 34676025

Modulation of KRAS Mutant by Inhibiting PLK1 Kinase in Cancer Therapeutics.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2021        PMID： 34676025      PMCID： PMC8521617          DOI： 10.1021/acsmedchemlett.1c00442

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  5 in total

1.  WEE1 kinase inhibitor shows promise.

Authors:  Peter Sidaway
Journal:  Nat Rev Clin Oncol       Date:  2019-10       Impact factor: 66.675

2.  Cdk1 plays matchmaker for the Polo-like kinase and its activator SPAT-1/Bora.

Authors:  Nicolas Tavernier; Costanza Panbianco; Monica Gotta; Lionel Pintard
Journal:  Cell Cycle       Date:  2015-06-03       Impact factor: 4.534

3.  Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1.

Authors:  Kristina A Cole
Journal:  Cancer Res       Date:  2020-02-01       Impact factor: 12.701

Review 4.  Structure-activity relationships of Wee1 inhibitors: A review.

Authors:  Xingkai Du; Jian Li; Xiaojiao Luo; Rong Li; Feng Li; Yiwen Zhang; Jianyou Shi; Jun He
Journal:  Eur J Med Chem       Date:  2020-07-10       Impact factor: 6.514

Review 5.  Playing polo during mitosis: PLK1 takes the lead.

Authors:  G Combes; I Alharbi; L G Braga; S Elowe
Journal:  Oncogene       Date:  2017-04-24       Impact factor: 9.867
  5 in total
  1 in total

1.  Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.

Authors:  Khayal Gasimli; Monika Raab; Morva Tahmasbi Rad; Elisabeth Kurunci-Csacsko; Sven Becker; Klaus Strebhardt; Mourad Sanhaji
Journal:  Int J Mol Sci       Date:  2022-09-17       Impact factor: 6.208
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.